Cost-Effectiveness of Sensor-Augmented Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in Italy

Sensor-augmented pump therapy (SAP) combines real time continuous glucose monitoring (CGM) with Continuous Subcutaneous Insulin Infusion (CSII) and provides additional benefits beyond those provided by CSII alone. SAP with automated insulin suspension provides early warning of the onset of hyperglycemia and hypoglycemia and has the functionality to suspend insulin delivery if sensor glucose levels are predicted to fall below a predefined threshold. Aim of this study was to assess the cost-effectiveness of SAP with automated insulin suspension versus CSII alone in type 1 diabetes.

Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - April 5, 2018 Category: Nutrition Authors: Nicolucci A, Rossi MC, D ’Ostilio D, Delbaere A, de Portu S, Roze S Source Type: research